ESMO BREAST CANCERVIRTUAL MEETING

Use of Physical Activity and Supportive Care among patients with early Breast Cancer reporting Cancer-Related Fatigue

Antonio Di Meglio¹, Cecile Charles¹, Elise Martin¹, Julie Havas¹, Arnauld Gbenou¹, Anne-Laure Martin², Sibille Everhard², Enora Laas³, Olivier Tredan⁴, Laurence Vanlemmens⁵, Christelle Jouannaud⁶, Christelle Levy⁷, Olivier Rigal⁸, Marion Fournier⁹, Patrick Soulie¹⁰, Agnes Dumas¹¹, Gwenn Menvielle¹², Fabrice André¹, Sarah Dauchy¹, Ines Vaz-Luis¹

¹Gustave Roussy, Villejuif, FR, ²UNICANCER, Paris, FR, ³Institut Curie, Paris, FR, ⁴Centre Léon Berard, Lyon, FR ⁵Centre Oscar Lambret, Lille, FR, ⁶Institut Jean Godinot, Reims, FR, ⁷Centre François Baclesse, Caen, FR, ⁸Centre Henri Becquerel, Rouen, FR, ⁹Institut Bergonié, Bordeaux, FR, ¹⁰Institut Paul Papin, Angers, FR, ¹¹Universite de Paris, Paris, FR, ¹²Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, FR



DISCLOSURES

Antonio Di Meglio

Honoraria from Thermo Fisher Scientific



RATIONALE AND STUDY AIM

- Cancer-related fatigue (CRF) is extremely prevalent among breast cancer survivors, and many of them describe CRF as severe¹
- . CRF has multiple domains -physical, emotional and cognitive- and generates considerable distress and impact on quality of life²
- Management of CRF includes (NCCN, ASCO, ESMO Guidelines):
 - Regular screening and assessment of CRF, patient education³
 - Maintaining adequate **Physical Activity** (PA) levels^{4,5}
 - Other **Supportive Care** options:
 - Psychosocial interventions (eg, cognitive-behavioral or psycho-education targeting non-adaptive thoughts)⁶
 - . Mind-body intervention techniques (eg, acupuncture)⁷
 - No data showing benefits of homeopathy for CRF
- Study aim: to describe the use of approaches that can help reduce CRF among patients with early-stage breast cancer that have completed primary cancer treatment

METHODS – STUDY POPULATION



CANTO (CANcer TOxicities; NCT01993498)

- prospective longitudinal cohort started in 2012
- 26 French comprehensive cancer centers
- dedicated national network sponsored by UNICANCER
- reached inclusion of **12012** patients in 2018

Inclusion criteria


- 18+ years old at breast cancer diagnosis
- Histologically confirmed invasive breast cancer
 - Stage I-II-III
- Untreated at time of inclusion (including primary surgery)

Exclusion criteria

- Stage IV
- · Local recurrence of BC
- History of other cancer within 5 years prior to study
 - Receipt of BC treatment prior to study entry

	Baseline	Follow-up after treatment				1 t t.ll	
Collected Information	Diagnosis	3-6 months	12 months	24 months	36 months	60 months	Long-term follow-up yearly for 5 years
Inclusion criteria							
Signed informed consent							
Clinical examination [^]							Prolonged and
Blood tests							long-term toxicity
Paraclinical examination							Survival Outcomes
Questionnaires (PROs)*							
Biological samples							





METHODS – STATISTICAL ANALYSIS

- Outcomes of interest: PA and Supportive Care between 3-6 months and 12 months after treatment completion
 - **1- PA behavior:** maintaining or increasing activity above recommended levels (≥10 MET-hours/week¹) vs. reducing activity below recommendations or remaining insufficiently active (<10 MET-hours/week); Global Physical Activity Questionnaire (GPAQ)-16
 - **2- Supportive Care consultations:** consulting a psychologist, acupuncturist or homeopath vs. not
- Independent variable: CRF assessed 3-6 months after treatment completion
 - 1- Global CRF: European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30
 - **2- CRF Physical, Emotional, and Cognitive domains:** EORTC QLQ-FA12
- Covariates:
 - **1- Assessed at breast cancer diagnosis (inclusion):** age, comorbidities, education, income, centre volume, breast cancer subtype and stage, breast and axillary surgery, receipt of chemotherapy
 - 2- Assessed 3-6 months after treatment completion Body Mass Index (BMI), anxiety and depression
- Statistical analysis: Multivariable logistic regression assessed odds of using PA and Supportive Care consultation by CRF status:
 i) Primary analysis- Severe CRF (EORTC QLQ score ≥40/100²) vs. not; ii) Sensitivity analysis- CRF as a continuous variable

ESMO BREAST CANCER VIRTUAL MEETING

RESULTS – STUDY COHORT

Overall CANTO enrol	ment 2012-2018	n= 12012
Mature follow-up until	12 months after treatment completion at time of analysis	n= 9702
	Exclude: Withdrew consent to study participation Non-respondents to CRF assessment 3-6 months	n= 11
	after treatment completion	n=1776
Overall cohort		n= 7915
	Data availability 12 months after treatment completion:	
	- Respondents to Physical Activity questionnaire	n= 6266 (79.1%)
		n= 6266 (79.1%) n= 6934 (87.6%)
	Respondents to Physical Activity questionnaire Providing Supportive care consultations data	

RESULTS – SELECT COHORT CHARACTERISTICS BY GLOBAL CRF

Characteristic N= 7915	Non-severe CRF group N= 5038 (63.6%)	Severe CRF group N= 2877 (36.3%)	p*
Mean Age, years (SD)	57.2 (11.1)	54.4 (11.2)	<.0001
Mean BMI (Kg/m²) (SD)	25.7 (5.1)	26.6 (5.9)	<.0001
Anxiety case Depression case	12.5% 1.9%	34.2% 15.5%	<.0001 <.0001
Charlson score ≥1	18.4%	21.3%	0.003
Household income ≥3000 €/month	44.2%	38.2%	<.0001
Stage III BC	9.4%	11.2%	<.0001
Mastectomy	25.5%	28.1%	0.010
Axillary dissection	35.9%	41.2%	<.0001
Receipt of chemotherapy	49.5%	58.0%	<.0001




RESULTS – PA AND SUPPORTIVE CARE CONSULTATIONS OVERALL

PA and supportive care between 3-6 and 12 months after treatment				
Overall N= 7915	(%)			
PA				
Insufficient activity (always <10*)	22.2%			
Reduced activity (from ≥10 to <10)	13.4%			
Maintained activity (always ≥10)	50.2%**			
Increased activity (from <10 to ≥10)	14.2%**			
, , , , , , , , , , , , , , , , , , ,	**Adherent to WHO recommendations on PA			
Supportive care				
Psychology consultations	9.8%			
Acupuncture consultations	7.7%			
Homeopathy consultations	7.5%			



RESULTS – PA BEHAVIOR BY GLOBAL CRF

after treatment



Maintaining or increasing PA above recommended levels (≥10 MET-hours/week)


Adjusted* Odds Ratio (aOR), (95% Confidence Interval [CI])


0.82 (0.72-0.94) p= 0.0037




RESULTS – SUPPORTIVE CARE BY GLOBAL CRF

Global CRF at 3-6 months after treatment







Supportive care consultations between 3-6 months and 12 months after treatment


aOR* (95% CI)	1.31 (1.07-1.59) p= 0.008
Times consulted	9 (14) vs. 7 (9)
Mean (SD)	p= 0.424

aOR* (95% CI)	1.50 (1.21-1.86) p= 0.0002
Times consulted	5 (6) vs. 5 (7)
Mean (SD)	p= 0.556

aOR* (95% CI)	1.55 (1.25-1.92) p<.0001
Times consulted	3 (4) vs. 3 (4)
Mean (SD)	p= 0.756





RESULTS – CRF DOMAINS







RESULTS – PA AND SUPPORTIVE CARE BY CRF DOMAIN







VIRTUAL MEETING



*Severe vs. Non-severe CRF group; Adjusted by: Age, BMI, anxiety and depression, comorbidities, education, income, centre volume, breast cancer subtype and stage, breast and axillary surgery, receipt of chemotherapy

RESULTS – SENSITIVITY ANALYSES: CRF AS CONTINUOUS

CRF domain	Mean score (SD)
Global	36.2 (25.7)
Physical	33.2 (24.3)
Emotional	23.3 (26.5)
Cognitive	18.0 (23.5)

Associations between CRF score, PA, and Supportive Care consultations; aOR* (95% CI)				
CRF domain	Maintaining or	SC consultations		
	increasing PA	Psychologist	Acupuncturist	Homeopath
Global	0.996 (0.993-0.998)	1.009 (1.005-1.013)	1.005 (1.000-1.011)	1.011 (1.009-1.014)
Physical	0.993 (0.983-0.996)	1.005 (1.000-1.011)	1.005 (0.999-1.011)	1.011 (1.008-1.015)
Emotional	1.00 (0.996-1.004)	1.006 (1.001-1.012)	1.003 (0.997-1.009)	1.001 (0.997-1.004)
Cognitive	1.005 (1.001-1.008)	1.004 (0.999-1.008)	1.003 (0.997-1.009)	0.999 (0.996-1.002)



STUDY LIMITATIONS

- Self-reported assessment of PA behavior (recall bias, risk of overestimation)
- Reason for consultation of supportive care specialist not collected; non-exhaustive information about all types of supportive care used
- . Cut-off for severe CRF (≥40/100) was validated for EORTC QLQ-C30, but not for CRF domains of EORTC QLQ-FA12
- Longitudinal nature of CANTO leads to some attrition over time (missing rates higher at later time points)



CONCLUSIONS

- More than 1/3 patients report severe global CRF 3-6 months post-treatment
- There is a relatively high rate of patients **not meeting PA recommendations** after treatment completion (>35%). Patients **reporting CRF seem less likely** to adhere to PA recommendations (aOR 0.82)
- Use of supportive care is **generally low** (7-10%). Severe CRF is associated **with higher odds of supportive care consultations**, but these were similar across practitioner types (aOR: psychologist 1.31, acupuncturist 1.50, homeopath 1.55)
- There are differences in use of PA and supportive care consultations **by CRF domain**: severe physical CRF is associated with lower adherence to PA (aOR 0.73), and emotional CRF is positively associated with psychology consultations (aOR 1.41)
- Use of some available strategies and uptake of recommendations to manage of CRF **seems suboptimal** among patients with early-stage breast cancer reporting CRF
- Lack of knowledge or resources and stigmatization regarding specific recommendations (eg, referral to a psychologist) may be partly responsible of these findings in a large contemporary cohort of cancer survivors

ESMO BREAST CANCER VIRTUAL MEETING

ACKNOWLEDGMENTS

Mentor

Ines Vaz-Luis

Breast Cancer Survivorship Research Group, Institut Gustave Roussy

Elise Martin Barbara Pistilli

Mayssam El-Mouhebb

Arnauld Gbenou

Julie Havas

Margarida Matias

Cecile Charles

Arlindo R Ferreira



Stefan Michiels Suzette Delaloge Agnes Dumas

Julia Bonastre

Dana-Farber Cancer Institute

Jennifer A Ligibel Ann H Partridge

Nancy U Lin

Memorial Sloan Kettering Cancer Center

Lee W Jones Sangkyu Lee

University of California - Los Angeles

Patricia A Ganz

GUSTAVE

University of Arizona

Tracy E Crane

Pierre Louis Institute of Epidemiology and

Public Health

Gwenn Menvielle Sandrine Pinto Thomas Boyagnet

Ospedale Policlinico San Martino

Lucia Del Mastro

UNICANCER

Sibille Everhard Anne Laure Martin

Jerome Lemonnier

CANTO Co-investigators

Patrick Arveux
Paul H Cottu

Anne Lesur

Olivier Tredan

Laurence Vanlemmens

Florence Joly

INSERM Unit 981

Director

Fabrice Andre

Inserm

ALL PATIENTS THAT PARTICIPATED IN CANTO



